The Additional Hetero Ring Consists Of Two Nitrogens And Three Carbons Patents (Class 514/341)
  • Patent number: 11452720
    Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: September 27, 2022
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Stephan D. Parent, Travis Houston
  • Patent number: 11401244
    Abstract: This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: August 2, 2022
    Assignee: RESEARCH TRIANGLE INSTITUTE
    Inventors: Scott P. Runyon, Rangan Maitra, Sanju Narayanan, James Barnwell Thomas
  • Patent number: 11339140
    Abstract: The present invention presents 2-(acylamino)imidazoles with therapeutic activity, including selective activity against cancer cells, and compositions comprising them. Methods of using and preparing the 2-(acylamino)imidazoles are also presented.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: May 24, 2022
    Assignees: Curza Global, LLC, The University of Utah
    Inventors: Ryan E. Looper, Justin M. Salvant, Emily K. Kirkeby, Wenxing Guo, Katrin P. Guillen, Bryan E. Welm
  • Patent number: 11330822
    Abstract: The present invention is directed to agricultural compositions containing clothianidin, at least one dispersant selected from the group consisting of sodium alkyl naphthalene sulfonate condensate, alkyl polyglycoside and a mixture thereof, an inorganic compound selected from the group consisting of attapulgite, magnesium aluminum silicate, silicon dioxide and aluminum oxide and glycerol. The present invention is further directed to compositions containing clothianidin, at least one dispersant selected from the group consisting of sodium alkyl naphthalene sulfonate condensate, alkyl polyglycoside and a mixture thereof, an inorganic compound selected from the group consisting of attapulgite, magnesium aluminum silicate, silicon dioxide and aluminum oxide, glycerol and at least one liquid fertilizer.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 17, 2022
    Assignee: VALENT U.S.A., LLC
    Inventors: Xiaomeng Liu, Xiaonan Duan, Alice Wei
  • Patent number: 11267789
    Abstract: This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: March 8, 2022
    Assignee: RESEARCH TRIANGLE INSTITUTE
    Inventors: Scott P. Runyon, Rangan Maitra, Sanju Narayanan, James Barnwell Thomas
  • Patent number: 11266647
    Abstract: The present invention relates to a method of increasing cell proliferation in a population of pancreatic beta cells and a method of treating a subject for a condition associated with an insufficient level of insulin secretion. Also disclosed is a composition. The composition includes a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1 A) inhibitor and a transforming growth factor beta (TGFP) superfamily signaling pathway inhibitor.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: March 8, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Andrew F. Stewart, Peng Wang
  • Patent number: 11253562
    Abstract: The present invention relates to a feed supplement or a food supplement which comprises a resin acid based composition comprising over 10% (w/w) resin acids for use in in the prevention of intestinal disorders. The invention further relates to a use of the feed supplement or the food supplement and a feed composition or a food composition comprising the feed supplement or the food supplement, respectively.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: February 22, 2022
    Assignees: Forchem Oy, Hankkija Oy
    Inventors: Mikko Rintola, Juha Orte, Juhani Vuorenmaa
  • Patent number: 11155523
    Abstract: Provided is a CCR2/CCR5 receptor antagonist and the use thereof in the preparation of a drug for treating diseases associated with the CCR2/CCR5. In particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: October 26, 2021
    Assignee: Medshine Discovery, Inc.
    Inventors: Yunfu Luo, Yuyong Ba, Shuhui Chen
  • Patent number: 11013737
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 25, 2021
    Assignee: CALCIMEDIA, INC.
    Inventors: Gonul Velicelebi, Kenneth Stauderman, Michael Dunn, Jack Roos
  • Patent number: 10981889
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: April 20, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Aves, Benjamin Gerald Tehan
  • Patent number: 10973818
    Abstract: Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: April 13, 2021
    Assignee: CALCIMEDICA, INC.
    Inventors: Gonul Velicelebi, Kenneth Stauderman, Michael Dunn, Jack Roos
  • Patent number: 10806728
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: October 20, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10807965
    Abstract: The present invention relates to a process for the preparation of apalutamide. In particular, the present invention relates to a process for the preparation of apalutamide and its intermediates. The present invention also relates to pharmaceutical compositions comprising apalutamide.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: October 20, 2020
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Kumar Kamlesh Singh, Nikhil Amar Singh, Ganpat Dan Shimbhu Charan, Nimeshkumar Mukeshkumar Shah
  • Patent number: 10787419
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: September 29, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: George Kunos, Malliga Iyer, Resat Cinar, Kenner C. Rice
  • Patent number: 10766860
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: September 8, 2020
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson, David Lonergan
  • Patent number: 10750740
    Abstract: A formulation is provided comprising a) at least one agriculturally active ingredient; b) at least one amide of formula (I) wherein R1 is selected from the group consisting of a non-aromatic hydrocarbyl group having from 1 to 16 carbon atom and benzyl; R2 is selected from the group consisting of a hydrocarbyl group having from 1 to 4 carbon atoms and benzyl; and R3 is selected from the group consisting of hydrogen and a hydrocarbyl group having from 1 to 16 carbon atoms and c) at least one acyl morpholine according to the formula (II), wherein R is H, CH3 or C2H5. A method for treating a plant or seed with such formulation is also provided.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: August 25, 2020
    Assignee: NOURYON CHEMICALS INTERNATIONAL B.V.
    Inventors: Peter Westbye, Karin Hammarstrand, Martina Andersson
  • Patent number: 10722448
    Abstract: A method of treating the skin or hair on a dog containing an effective amount of an ectoparasiticide previously applied to the skin or hair, comprising applying a quantity of a cleansing composition directly to the skin or hair, wherein the treatment does not result in reducing the efficacy of the ectoparasiticide against adult fleas (C. felis) or adult ticks (R. sanguineus) below 90% efficacy for at least a month after application of the ectoparasiticide; wherein the cleansing composition comprises about 1-3% glycerin; about 2-4% silicone copolyol esters, water and is essentially free of surfactant.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: July 28, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventor: Eric Anthony Hansen
  • Patent number: 10648985
    Abstract: Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: May 12, 2020
    Assignee: Life Technologies Corporation
    Inventors: Kyle Gee, Upinder Singh, Scott Grecian, Scott Clarke
  • Patent number: 10588899
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: March 17, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10584119
    Abstract: The present invention comprises compounds of Formula I and their use in the inhibition of cell proliferation in therapeutic treatments. Pharmaceutical compositions comprising at least one compound of Formula I and at least one pharmaceutical excipient are disclosed, as well as methods of using compounds of Formula I and pharmaceutical compositions thereof for treatment of hyper-proliferative diseases and other disorders.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: March 10, 2020
    Assignee: Translational Drug Development, LLC
    Inventors: Tong Wang, Stephen Gately
  • Patent number: 10543196
    Abstract: In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: January 28, 2020
    Assignee: Astellas Deutschland GmbH
    Inventors: Jeffrey Colledge, Margaretha Olthoff
  • Patent number: 10537558
    Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and/V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by “a”, R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the eIF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: January 21, 2020
    Assignee: Bantam Pharmaceutical, LLC
    Inventors: M. Arshad Siddiqui, Stephane Ciblat, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Xiangyu Guo, Sanjay Srivastava, Gerald W. Shipps, Alan B. Cooper, Nicolas Bruneau-Latour, Vu Linh Ly
  • Patent number: 10513496
    Abstract: The invention relates to a composition comprising at least one aminobenzamide compound or a salt thereof for controlling animal parasites, veterinary pharmaceutical compositions comprising at least one aminobenzamide of formula (I) for preventing infection with diseases transmitted through parasites, its use for the preparation of a veterinary pharmaceutical for controlling animal parasites, and a method for preventing infection with diseases transmitted through parasites.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: December 24, 2019
    Assignee: Bayer Animal Health GmbH
    Inventors: Ulrich Görgens, Akihiko Yanagi, Katsuaki Wada, Tetsuya Murata, Yukiyoshi Watanabe, Jun Mihara, Koichi Araki
  • Patent number: 10508100
    Abstract: The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: December 17, 2019
    Assignee: Gilead Sciences, Inc.
    Inventor: Gregory Notte
  • Patent number: 10435374
    Abstract: The present application relates to the use of heterocyclic compounds for controlling animal pests including arthropods, insects and nematodes, to novel heterocyclic compounds, to processes for their preparation and to intermediates for preparing the heterocyclic compounds.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: October 8, 2019
    Assignee: BAYER CROPSCIENCE AG
    Inventors: Eike Kevin Heilmann, Joerg Greul, Axel Trautwein, Hans-Georg Schwarz, Isabelle Adelt, Roland Andree, Peter Luemmen, Maike Hink, Martin Adamczewski, Mark Drewes, Angela Becker, Arnd Voerste, Ulrich Goergens, Kerstin Ilg, Johannes-Rudolf Jansen, Daniela Portz
  • Patent number: 10428057
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: October 1, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael J. Soth, Gang Liu, Kang Le, Jason Cross, Philip Jones
  • Patent number: 10351557
    Abstract: The present invention relates to compounds of the formula (I), to the use of compounds of the formula (I) in electronic devices, and to electronic devices containing one or more compounds of the formula (I). The invention furthermore relates to preparation processes for compounds of the formula (I) and to formulations comprising one or more compounds of the formula (I).
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: July 16, 2019
    Assignee: Merck Patent GmbH
    Inventors: Rocco Fortte, Christof Pflumm, Constanze Brocke, Amir Hossain Parham
  • Patent number: 10347387
    Abstract: Graphene, a composition for preparing graphene, and a method of preparing graphene using the composition are disclosed.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: July 9, 2019
    Assignee: HANWHA AEROSPACE CO., LTD.
    Inventors: Dukhwa Na, Dongkwan Won, Euisoo Park, Jaechul Ryu
  • Patent number: 10238636
    Abstract: The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ASK1 inhibitor in combination with a FXR agonist, to a patient in need thereof.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: March 26, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Jamie Geier Bates, David Gordon Clarkson Breckenridge, John T. Liles, William J. Watkins
  • Patent number: 10233182
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 19, 2019
    Assignee: X-Rx, Inc.
    Inventors: Lee Babiss, Matthew Clark, Anthony D. Keefe, Mark J. Mulvihill, Haihong Ni, Louis Renzetti, Frank Ruebsam, Ce Wang, Zhifeng Xie, Ying Zhang
  • Patent number: 10226438
    Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: March 12, 2019
    Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Thomas S. Scanlan, Meredith Hartley, Andrew Placzek, Marco Righi, Dennis Bourdette, Gail Marracci, Priya Chaudhary
  • Patent number: 10207996
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: February 19, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • Patent number: 10184134
    Abstract: Soybean plants comprising event SYHT0H2, methods of detecting and using the same, and soybean plants comprising a heterologous insert at the same site as SYHT0H2.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: January 22, 2019
    Assignee: Syngenta Participations AG
    Inventors: John Daniel Hipskind, Kristina Burgin, Rakesh Jain, Karolyn Terpstra, Marina Sigareva, Annick Jeanne De Framond, Becky Breitinger, Vance Cary Kramer, Weining Gu
  • Patent number: 10125100
    Abstract: There are provided compounds of formulas III and VIIa: or a salt or protected derivative thereof, wherein Z2 represents a structural fragment of formula V, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: November 13, 2018
    Assignees: Topivert Pharma Limited
    Inventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
  • Patent number: 10093668
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 9, 2018
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Rama K. Mishra, Leonidas C. Platanias, Javier Izquierdo-Ferrer
  • Patent number: 10092546
    Abstract: The present invention relates to compounds of formula I wherein R1? is CH3; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tertbutyl, cyclopropyl, hydroxmethyl, or 2-propyl-2-ol; R3 is Cl, F, CF3, methyl, methoxy, isopropyl, cyano or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: October 9, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marius Hoener, Juergen Wichmann
  • Patent number: 10047071
    Abstract: A dihydropyrimidinone derivative includes a compound having a chemical structure according to Formula 1: Z is selected from O, S and N; Y is N X is selected from O and S; and R represents aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the substituted aryl or substituted heteroaryl have one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, hydroxyl, alkylthio, alkylamino, heteroaryl, aryloxy, haloaryloxy, arylthio, arylamino, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: August 14, 2018
    Assignee: KING SAUD UNIVERSITY
    Inventors: Mashooq Ahmad Bhat, Mohamed A. Al-Omar
  • Patent number: 10018637
    Abstract: Provided herein are methods for predicting the clinical sensitivity of an inflammatory disease (e.g., ankylosing spondylitis) and a subject's response to treatment with apremilast using the level of a biomarker (e.g., MCP1). Also provided herein are methods for treating an inflammatory disease.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: July 10, 2018
    Assignee: CELGENE INTERNATIONAL II SARL
    Inventors: Peter H. Schafer, Matthew William Burnell Trotter
  • Patent number: 9988366
    Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoismers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: June 5, 2018
    Assignee: Syngenta Participations AG
    Inventors: Michel Muehlebach, Ruud Titulaer, Daniel Emery, Andrew Edmunds, Andre Stoller, Pierre Joseph Marcel Jung, Anke Buchholz, Peter Renold
  • Patent number: 9944604
    Abstract: The invention relates to a composition comprising at least one aminobenzamide compound or a salt thereof for controlling animal parasites, veterinary pharmaceutical compositions comprising at least one aminobenzamide of formula (I) for preventing infection with diseases transmitted through parasites, its use for the preparation of a veterinary pharmaceutical for controlling animal parasites, and a method for preventing infection with diseases transmitted through parasites.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: April 17, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Görgens, Akihiko Yanagi, Kazue Yanagi, Keisuke Yanagi, Kasumi Yanagi, Katsuaki Wada, Tetsuya Murata, Yukiyoshi Watanabe, Jun Mihara, Koichi Araki
  • Patent number: 9931329
    Abstract: Phenyl triazole derivative (specifically, 1-[6-[[5-(2-fluorophenyl)-3-methyl-triazol-4-yl]methoxy]-3-pyridyl]imidazole-4-carbonitrile or a pharmaceutically acceptable salt thereof), pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: April 3, 2018
    Assignee: SANIONA A/S
    Inventors: Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen
  • Patent number: 9913835
    Abstract: The present invention relates to methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells. Specifically, the invention relates to methods of using compounds comprising a N-(1H-pyrazol-4-yl)-nicotinamide moiety having a Formula I: and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: March 13, 2018
    Assignee: Frequency Therapeutics, Inc.
    Inventors: Christopher Loose, Will McLean, Melissa Hill-Drzewi
  • Patent number: 9867801
    Abstract: Provided is an amorphous solid dispersion including a taxane or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymer, and a pharmaceutically acceptable surfactant, which has enhanced solubility. Also provided is a method for preparing the solid dispersion. The present subject matter also provides a tablet having good solubility, bioavailability and stability, which comprises the amorphous solid dispersion, an intragranular excipient, and an extragranular excipient.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: January 16, 2018
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Shanmugam Srinivasan, Ho Taek Im, Young Su Yoon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: 9844218
    Abstract: Provided herein are compounds that exhibit activity as acetyl-CoA carboxylase modulators (e.g., inhibitors) and are useful, for example, in methods for the control of fungal pathogens in plants.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: December 19, 2017
    Assignee: Monsanto Technology LLC
    Inventors: Urszula Slomczynska, Matthew W. Dimmic, William P. Haakenson, Jr., Jennifer L. Bennett, Barry J. Shortt, Christina M. Taylor, Deryck Jeremy Williams, Martin Slater
  • Patent number: 9820486
    Abstract: Compositions and processes for controlling nematodes are described herein, e.g., nematodes that infest plants or animals. The compounds include oxazoles, oxadiazoles and thiadiazoles.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: November 21, 2017
    Assignee: Monsanto Technology LLC
    Inventors: Urszula Slomczynska, Matt W. Dimmic, Al Wideman, William P. Haakenson, Jr.
  • Patent number: 9790202
    Abstract: The present invention relates to novel anthranilamide derivatives of the general formula (I) in which R1, R2, R3, R4, R5, R6, A, Q, Y and n are each as defined in the description—, to the use thereof as insecticides and acaricides for control of animal pests, and to several processes for preparation thereof.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: October 17, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Rüdiger Fischer, Ernst Rudolf Gesing, Christoph Grondal, Markus Heil, Heinz-Juergen Wroblowsky, Arnd Voerste, Ulrich Gorgens
  • Patent number: 9771328
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which exhibits apoptosis signal-regulating kinase (“ASK1”) inhibitory activity and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis. The disclosure also provides compounds that are synthetic intermediates.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: September 26, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventor: Joshua R. Dunetz
  • Patent number: 9708288
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes related thereto.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: July 18, 2017
    Assignee: Dow AgroSciences LLC
    Inventors: Ann M. Buysse, Noormohamed M. Niyaz, David A. Demeter, Yu Zhang, Martin J. Walsh, Asako Kubota, Ricky Hunter, Tony K. Trullinger, Christian T. Lowe, Daniel I. Knueppel, Akshay Patny, Negar Garizi, Paul Renee LePlae, Jr., Frank J. Wessels, Ronald Ross, Jr., Carl DeAmicis, Peter Borromeo
  • Patent number: 9701657
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: July 11, 2017
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 9681658
    Abstract: An agrochemical formulation comprising a penetrant and an agrochemical active. The penetrant is an esterified and/or etherified polyol alkoxylate obtainable by directly esterifying and/or etherifying a polyol alkoxylate. There is also provided a method of making the penetrant comprising alkoxylation of a polyol, and esterification or etherification of the formed poyol alkoxylate. The penetrant is suitable for use in agrochemical formulations to enhance penetration of the active across a leaf cuticle.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: June 20, 2017
    Assignee: Croda International PLC
    Inventors: Trevor Graham Blease, Kathryn Marie Knight